You are here: Home » Companies » News

Sun Pharma, ICGEB tie up to develop dengue vaccine

Sun Pharma will fund and support further development of the vaccine

Drug major on Wednesday announced a new collaboration with International Centre for Genetic Engineering and Biotechnology (ICGEB) for development of vaccine targeted against all four serotypes of the virus.

will fund and support further development of the vaccine candidate and existing knowhow and patents. will grant exclusive rights and licences for development and commercialisation of this vaccine globally.

will receive pre-defined royalty and milestone payments.

"has developed a tailored recombinant virus-like particle (VLP) based tetravalent vaccine... has conducted pre-clinical studies over the past seven years and developed the existing knowhow and patents for this vaccine candidate. This is the second collaboration between and focusing on dengue," said.

"The first one announced in May 2016 was related to the development of a botanical drug for treatment of dengue. The current collaboration is focussed on developing a novel, safe and effective vaccine for prevention of dengue."

said the initial findings of ICGEB's vaccine indicate that the candidate induces serotype-specific non-cross-reactive and strongly neutralising antibodies without disease enhancing concerns.

"These features of the candidate vaccine differentiate this vaccine development programme from other vaccine programmes that are developed or in development globally. This vaccine development will focus on suitability for all target population whether previously affected or non-affected, including paediatric and adults and traveller population," it added.

said a joint development committee, comprising members of both the organisations will be established to provide oversight to the vaccine development programme.

According to the agreement signed, will disclose and make available to all such existing knowhow as well as effective completion of technology transfer by to within stipulated timeframe.

Since is not related to promoter / promoter group / group of Sun Pharma, this transaction does not fall under related party transaction, the company added.

image
Business Standard
177 22
Business Standard

Sun Pharma, ICGEB tie up to develop dengue vaccine

Sun Pharma will fund and support further development of the vaccine

Press Trust of India  |  New Delhi 

Pharmaceutical tablets and capsules
Pharmaceutical tablets and capsules

Drug major on Wednesday announced a new collaboration with International Centre for Genetic Engineering and Biotechnology (ICGEB) for development of vaccine targeted against all four serotypes of the virus.

will fund and support further development of the vaccine candidate and existing knowhow and patents. will grant exclusive rights and licences for development and commercialisation of this vaccine globally.



will receive pre-defined royalty and milestone payments.

"has developed a tailored recombinant virus-like particle (VLP) based tetravalent vaccine... has conducted pre-clinical studies over the past seven years and developed the existing knowhow and patents for this vaccine candidate. This is the second collaboration between and focusing on dengue," said.

"The first one announced in May 2016 was related to the development of a botanical drug for treatment of dengue. The current collaboration is focussed on developing a novel, safe and effective vaccine for prevention of dengue."

said the initial findings of ICGEB's vaccine indicate that the candidate induces serotype-specific non-cross-reactive and strongly neutralising antibodies without disease enhancing concerns.

"These features of the candidate vaccine differentiate this vaccine development programme from other vaccine programmes that are developed or in development globally. This vaccine development will focus on suitability for all target population whether previously affected or non-affected, including paediatric and adults and traveller population," it added.

said a joint development committee, comprising members of both the organisations will be established to provide oversight to the vaccine development programme.

According to the agreement signed, will disclose and make available to all such existing knowhow as well as effective completion of technology transfer by to within stipulated timeframe.

Since is not related to promoter / promoter group / group of Sun Pharma, this transaction does not fall under related party transaction, the company added.

RECOMMENDED FOR YOU

Sun Pharma, ICGEB tie up to develop dengue vaccine

Sun Pharma will fund and support further development of the vaccine

Sun Pharma will fund and support further development of the vaccine Drug major on Wednesday announced a new collaboration with International Centre for Genetic Engineering and Biotechnology (ICGEB) for development of vaccine targeted against all four serotypes of the virus.

will fund and support further development of the vaccine candidate and existing knowhow and patents. will grant exclusive rights and licences for development and commercialisation of this vaccine globally.

will receive pre-defined royalty and milestone payments.

"has developed a tailored recombinant virus-like particle (VLP) based tetravalent vaccine... has conducted pre-clinical studies over the past seven years and developed the existing knowhow and patents for this vaccine candidate. This is the second collaboration between and focusing on dengue," said.

"The first one announced in May 2016 was related to the development of a botanical drug for treatment of dengue. The current collaboration is focussed on developing a novel, safe and effective vaccine for prevention of dengue."

said the initial findings of ICGEB's vaccine indicate that the candidate induces serotype-specific non-cross-reactive and strongly neutralising antibodies without disease enhancing concerns.

"These features of the candidate vaccine differentiate this vaccine development programme from other vaccine programmes that are developed or in development globally. This vaccine development will focus on suitability for all target population whether previously affected or non-affected, including paediatric and adults and traveller population," it added.

said a joint development committee, comprising members of both the organisations will be established to provide oversight to the vaccine development programme.

According to the agreement signed, will disclose and make available to all such existing knowhow as well as effective completion of technology transfer by to within stipulated timeframe.

Since is not related to promoter / promoter group / group of Sun Pharma, this transaction does not fall under related party transaction, the company added.
image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard